Procter & Gamble is set to acquire supplement maker Thorne for $3.8 billion, a move designed to significantly enhance its footprint in the burgeoning beauty and wellness sector. This strategic acquisition aligns with P&G's objective to expand its portfolio in areas where demographic trends favor growth.

P&G Chief Executive Shailesh Jejurikar highlighted on CNBC that the company is actively pursuing a more substantial role in its beauty and health businesses. Thorne, currently owned by private-equity firm L Catterton since 2023, offers a diverse range of supplements, including creatine, prenatal vitamins, and hormone-related products. The acquisition signals P&G's commitment to capitalizing on the increasing consumer demand for health and wellness products.

The deal underscores P&G's strategy to diversify beyond its traditional consumer staples and tap into higher-growth markets. Thorne's established presence and product line in the supplement industry make it an attractive asset for P&G, aiming to leverage Thorne's expertise and customer base to accelerate growth in the health and wellness space. This acquisition is expected to be a key driver of future revenue for the consumer goods giant.